Cti Biopharma reported $32.05M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Applied Genetic Technologies AGTC:US USD 34.24M 12.12M
Baxter International BAX:US USD 1.6B 251M
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Cti Biopharma CTIC:US USD 32.05M 34.04M
Cytori Therapeutics CYTX:US USD 20.27M 2.18M
Eli Lilly And LLY:US USD 2.62B 5.5M
Geron GERN:US USD 61.47M 14.59M
Mirati Therapeutics MRTX:US USD 173.53M 71.97M
Northwest Biotherapeutics NWBO:US USD 9.42M 4.59M
Novartis NOVN:VX USD 8.73B 5.1B
Novartis NVS:US USD 8.73B 5.1B
Seattle Genetics SGEN:US USD 362.6M 2.27M
Teva Pharmaceutical Industries TEVA:US USD 2.22B 167M
YTE INCY:US USD 2.69B 255.24M